RX Drugs Information:

DRUG DESCRIPTION

EYLEA (aflibercept) is a recombinant fusion protein consisting of portions
of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion
of human IgG1 formulated as an iso-osmotic solution for intravitreal administration.
Aflibercept is a dimeric glycoprotein with a protein molecular weight of 97
kilodaltons (kDa) and contains glycosylation, constituting an additional 15%
of the total molecular mass, resulting in a total molecular weight of 115 kDa.
Aflibercept is produced in recombinant Chinese hamster ovary (CHO) cells.